Summary Progress in our understanding of the contribution of P-glycoprotein (P-gp)-mediated resistance to chemotherapy failure in haematological as well as solid tumours has been hampered by the lack of highly sensitive, reliable methods for the detection of P-gp function in fresh human tumour cells. The present study identifies the novel nucleic acid stain SYT016 as a highly sensitive and specific dye to assess P-gp function. The effect of P-gp is expressed here as the ratio of dye fluorescence (RF) from cells incubated with dye with or without 2 gM of the P-gp inhibitor PSC 833. Using flow cytometric analysis, an RF of 0.9 was found for SYT016 in the KB3-1 (P-gp-) and 1.6 in KB8 (P-gp+) cells. Three types of patients' cells were studied: (1) in haematopoietic CD34+ cells, which are known to express P-gp, the RF was 6.0 for SYTO16 compared with 2.5 for rhodamine 123 and 1.3 for daunorubicin (mean of five individuals); (2) in acute myeloid leukaemia cells, the RF for SYTO16 was 1.0 in P-gp-and 4.5 in P-gp+ samples; (3) for the first time, we have quantitated P-gp function in fresh human solid tumour (sarcoma) cells. We found, in a P-gp+ leiomyosarcoma, an RF of 16 for SYT016 and 2.7 for daunorubicin. This means that complete inhibition of P-gp function in these sarcoma cells would lead to an increase of daunorubicin accumulation with 170% compared with 30% in the CD34+ cells. Next, we showed that SYTO16 could be fixed in nuclei by 3.6% formaldehyde treatment, allowing quantification of the nuclear fluorescence on cytospins by laser scanning microscopy. In conclusion, SYTO16 proved to have a combination of favourable properties: it can be excited at 488 nm and has large fluorescence enhancement upon binding to nucleic acids, allowing the use of low, nontoxic (< 10 nM) concentrations. Because the RF for SYT016 is much higher than for daunorubicin, it can be applied for the determination of P-gp function in relatively small numbers of low-P-gp-expressing tumour cells by laser scanning microscopy. Individual sarcomas were found to have high P-gp function compared with CD34+ cells. This assay may be used to select patients for P-gp modulation protocols.
The putative role of P-glycoprotein (P-gp) in chemotherapy resistance of human cancer has been studied extensively since P-gp was discovered (Juliano and Ling, 1976) . In particular, the availability of monoclonal antibodies (Kartner et al, 1985; Scheper et al, 1988) and gene probes (Noonan et al, 1990 ) has greatly stimulated studies that have addressed the expression of P-gp in human tumour cells. Most of these studies correlate P-gp expression with clinical parameters, such as response to chemotherapy, duration of response or survival. Such studies are important because they may provide a rationale to adapt the treatment of patients predicted to have a poor response. In particular, the selection of patients for clinical trials with chemotherapy regimens aimed to circumvent or overcome the drug efflux by P-gp may be guided by measurements of P-gp levels in the patients' tumour cells. Progress in our understanding of the impact of P-gp on the response of cancer patients to chemotherapy is hampered by the inadequacy of current analytical methods to determine tumour cell P-gp in a quantitative, sensitive and reproducible way (Beck et al, 1996) . A further improvement of immunocyto-/histochemical techniques to study low levels of P-gp expression is necessary (Beck et al, 1996; Broxterman et al, 1996a ). An alternative approach to study the impact of P-gp expression is to measure the P-gp-mediated drug efflux in tumour cells. Such functional P-gp assays have been extensively used to assess drug transporter activity in cell lines and more recently in normal haematopoietic cells (Neyfakh et al, 1989; Chaudhary and Roninson, 1991) and haematological malignancies (Marie et al, 1993; Ross et al, 1993; Ino et al, 1994; Leith et al, 1995) . These assays are based on the ability of P-gp to export fluorescent dyes, such as rhodamine 123, out of cells, allowing a convenient flow cytometric determination of P-gp activity. Whereas these fluorescent dyes are used to detect the P-gp activity in leukaemic cells (Broxterman et al, 1996 a and b) , the specific problems with solid tumours, such as the difficulty to obtain single-cell suspensions leave this type of assay still largely unexplored (Broxterman et al, 1990; Kunikane et al, 1995) . The lack of P-gp functional assays and of reliable immunohistochemical detection of P-gp has precluded definitive conclusions on the role of P-gp in solid tumours (Beck et al, 1996) . Our purpose was to devise a sensitive functional P-gp assay, applicable to the study of different types of tumour cells. We describe the use of a novel nucleic acid stain that appears to be a highly sensitive and specific probe for P-gp function in haematological as well as solid tumour cells; as it can be excited at 488 nm and fixed in the cells, quantitative analysis of 
Patient material
Three types of cells were studied, namely human peripheral CD34+ cells, acute myeloid leukaemia (AML) and freshly dissociated sarcoma cells. Leucapheresis samples were obtained from patients with haematological and oncological malignancies.
Patients were treated with granulocyte colony-stimulating factor (G-CSF) and/or chemotherapy, resulting in increased numbers of CD34+ cells in peripheral blood. These CD34+ cells were isolated from leucapheresis samples after overmight storage at 4°C, using the MiniMacs System (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. The purity was always > 90% CD34+, as determined by flow cytometric analysis. Blood samples obtained from patients with AML were subjected to Ficoll separation, and the nucleated cells were used immediately for the P-gp assays or frozen in liquid nitrogen and thawed as described (Broxterman et al, 1996b) . Tumour tissue (10-15 g) from two leiomyosarcomas (sarcoma 1 and 3, Table 1) and one liposarcoma (sarcoma 2, Table 1 ) was dissociated immediately after resection by collagenase-DNAase I treatment, according to described methods (Broxterman et al, 1995) . The resulting cell suspensions were used for P-gp analysis immediately after dissociation (3-4 h after tumour resection) or for comparison after ovemight storage at 4°C (sarcoma 1), after freezing and thawing (sarcoma 1) or after keeping cells for 1 week in RPMI plus 20% FCS and glutamine at 37°C (sarcoma 3).
Clonogenic assay
The clonogenic capacity of the CD34+ cells was assayed in semisolid medium in the presence of 5% placenta-conditioned medium (3000-9000 cells per ml). Colonies (> 40 cells) and clusters (8-40 cells) were scored after 12 days. To study the toxicity of SYTO16, CD34+ cells were incubated for 45 min (the time chosen by us for dye loading in P-gp activity assays) with increasing concentrations of the dye and were washed and plated for 12 days in the clonogenic assay.
Dyes
Daunorubicin was from Specia (Paris) and rhodamine 123 (Rhol23) was from Sigma (St Louis, MO, USA (Feller et al, 1995b) . No effect of these agents was seen in the HL60/ADR or the parental cell line (Table 1) . These data show the specificity of SYTO13 and SYTO16 as substrates for P-gp.
More detailed investigations of the dyes were carried out using the KB8 cells, which is the cell line with the lowest P-gp overexpression available to us (Noonan et al, 1990 ). SYTO13 and SYTO16 behaved in a very similar way. The time course of SYTO16 accumulation in KB8 cells is shown in Figure 1 . Steadystate accumulation of both dyes was reached within 30 min, with or without 2 gM PSC 833. The 45-min accumulation of both dyes was linear with the loading concentration being at least 1-25 nM (data not shown). Next, we compared the sensitivity of SYTO13 and SYTO16 with fluorescent dyes that are commonly used for flow cytometric measurement of P-gp activity in leukaemias. Table 1 shows that the increase of fluorescence of the SYTO dyes in KB8 cells after P-gp inhibition with PSC 833 was of similar magnitude as that of Rhol23 and DiOC2(3).
Cells from patients
As the ratio of active to passive drug transport, which largely determines the net modulator effect, may be very different for different cell types (and is actually low for daunorubicin in the KB cells; Spoelstra et al, 1992), we applied the present test to some categories of cells for which it may be of value: normal human (CD34+) cells, AML blasts and freshly dissociated solid tumour (sarcoma) cells. Four AMLs were selected for P-gp expression based on the MRK-16 labelling index -two with MRK-16 index 1.7, which is a value associated with low or absent functional P-gp activity in AMLs as measured in a Rhol23 test (Broxterman et al, 1996b) , and two AMLs with a high MRK-16 index (7.9 and 9.0). It appeared that the modulation factor by PSC 833 in the P-gp+ human tumour samples and CD34+ cells was higher for SYTO16 than for Rhol23 (Table 1) . One of the leiomyosarcomas (sarcoma 1), which had a very high P-gp expression as measured with MRK-16 (see legend Table 1 ), also showed a large response to PSC 833, in particular when SYTO16 was used as P-gp substrate. The daunorubicin modulation of these cells was 2.7, which means that after P-gp inhibition these cells take up almost three times more daunorubicin. Such a large modulation has not been seen before, by us, in AML cells (Broxterman et al, 1996b) , and the modulation was also much lower in the CD34+ cells. In addition, for this sarcoma, the P-gp function was compared in fresh cells, cells that had been stored overnight at 4°C and cells that were thawed after freezing in liquid nitrogen. As shown in Table 1 , there was excellent agreement between the samples. A second leiomyosarcoma (sarcoma 3) had a P-gp activity similar to that of CD34+ cells, and a liposarcoma (sarcoma 2) was P-gp negative. In conclusion, these results show for the first time quantitative data on P-gp activity in fresh human solid tumour cells and allow an estimation of the impact of P-gp on drug accumulation in these tumours.
Confocal laser scanning microscopy Cell lines
The flow cytometric method used to detect P-gp function established SYTO16 as a sensitive P-gp activity probe for solid tumours when a high yield of viable single cells is available. CLSM may be an alternative when only a small number of cells is available, provided that the method is sensitive and reliable. Therefore, we compared a CLSM method for the quantification of nuclear-fixed SYTO16 with flow cytometric data. We have previously shown that the low sensitivity of daunorubicin as a P-gp probe precluded the accurate measurement of the PSC 833 effect in KB8 cells, as well as in most AML samples, by CLSM analysis of about 200 cells (Broxterman et al, 1997) . Using SYTO16 in KB8 cells, the development of fluorescence in individual cells was first followed qualitatively in real time before and after the addition of PSC 833 and after fixation. The increase in cellular SYTO16 fluorescence upon addition of PSC 833 was clearly visible (Figure 2) . Moreover, after fixation, a large increase in nuclear fluorescence occurred, while the cytoplasmic fluorescence largely disappeared. To fully understand the biophysical nature of these changes, it would be necessary to study further the chemical interaction of SYTO16 with nucleic acids (DNA and RNA) under different conditions. Here, we take advantage of the fact that fixation of the dye allows a more practical assay. We found that the fluorescence was linear, at least within the range of concentrations of SYTO16 that are convenient to use (5-25 nM) (see Figure 3) . In practice, we used a slightly higher concentration than for flow cytometry for which 1-5 nm was satisfactory).
Cells from patients
To demonstrate some potential applications, we analysed P-gp function in CD34+ cells (an example is shown in Figure 4 ) and in AML samples (see Table 1 ). The ratios of the nuclear SYTO16 fluorescence with or without PSC 833 were 4.0 for CD34+ samples, 0.8 and 1.1 for the Pgp-and 4.8 and 4.5 for the Pgp+ AMLs. This method was also applied to the sarcoma cells. For example, in leiomyosarcoma 1, a PSC 833 effect on SYTO16 nuclear fluorescence of 10.7 was found by analysis of 204 cells without (mean nuclear fluorescence 5.2 ± 3.3) and 218 cells with PSC 833 (mean nuclear fluorescence 55.9 ± 16.3). The second leiomyosarcoma had a PSC 833 effect of 3.9 and the liposarcoma of 1.1 (Table 1) . The results measured with the flow cytometer correlated well with the CLSM method. The CLSM method can be used for combined staining of a plasma membrane antigen with nuclear staining of the P-gp probe.
Cytotoxicity assay
We determined the cytotoxicity of SYTO16 in a clonogenic assay for CD34+ cells from three individuals. No inhibition of clonogenicity was found at concentrations of SYTO16 up to 10 nm. (Chaudhary and Roninson, 1991) .
In summary, we have shown that SYTO16 is a highly sensitive probe for P-gp activity in a number of different experimental setups. In our present experiments, the sensitivity of the detection of P-gp function was higher than for Rho 123 in the tumour samples. It is not clear why the difference in sensitivity between both probes for different types of cells (e.g. compare AML4 and sarcoma 3) is not the same, but factors related to passive membrane transport of the probes might play a role. Another P-gp probe used previously by us is calcein-AM (Feller et al, 1995b ). As we found that the sensitivity was no higher for calcein-AM than for Rhol23, we have not used it in the present comparison. Probes other than Rhol23 may have advantages in certain experimental situations (e.g. DiOC2(3); Leith et al, 1995) . It is important to realize that, for any new combination of probe and modulator, one should be aware of putative interactions with the fluorescence of the probe not related to pump activity and appropriate controls have to be performed. We have discussed the theoretical and practical considerations of the different probes in a more comprehensive way in Broxterman et al (1997) .
Of importance, the present data show that the membrane integrity and the metabolic state of rapidly dissociated solid tumour cells is apparently sufficient to study P-gp activity. From previous experiments with human xenografts as a model (Broxterman et al, 1995) , these results were expected, but they have now been shown for the first time in primary human tumour cells. In particular, the large modulation of SYTO16 fluorescence after P-gp inhibition, combined with the possibility to measure nuclear-fixed dye at an excitation wavelength of 488 nm, allows the reliable analysis of a relatively small number of tumour cells by CLSM. The concomitant analysis of P-gp activity and protein expression with monoclonal antibodies in the same single cells is possible. Clearly, the presupposition is that viable tumour cell suspensions are available or can be prepared; in certain carcinomas (breast), this may not be the case or more elaborate techniques may have to be used (Ljung et al, 1989; Dairkee et al, 1995) .
In conclusion, we propose that the methodology described here to quantitate P-gp activity in normal as well as malignant blood cell populations and in solid tumour cells is superior because of its combination of simplicity and sensitivity. It may be used in clinical situations, such as the selection of patients for P-gp modulation protocols.
